Stock Forecast

  Medicenna Therapeutics Corp. ( MDNA) Stock. Should you Buy or Sell?    $ 0.97

0.01 (0.50 %)



Medicenna Therapeutics Corp. Analysis

Updated on 10-09-2022
Symbol MDNA
Price $0.97
Beta 0.366
Volume Avg. $287.77 thousand
Market Cap $67.67 M
52 Week Range $0.76 - $2.94


Medicenna Therapeutics Corp. opened the day at $0.97 which is +'0.50 % on yesterday's close. Medicenna Therapeutics Corp. has a 52 week high of $2.94 and 52 week low of $0.76, which is a difference of $2.18. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $67.67 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Medicenna Therapeutics Corp. for $67.67 M, it would take 15 years to get your money back. Medicenna Therapeutics Corp. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Medicenna Therapeutics Corp. Stock Forecast - Is Medicenna Therapeutics Corp. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value


PE Ratio -3.380
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing Medicenna Therapeutics Corp.


Price Book Value Ratio 3.822 Price To Book Ratio 3.822
Price To Sales Ratio 0.000 Price Earnings Ratio -3.380


How liquid is Medicenna Therapeutics Corp.


Current Ratio 9.350
Quick Ratio 9.034


Debt


Debt Ratio 0.107 Debt Equity Ratio 0.119
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000



Latest news about Medicenna Therapeutics Corp.


2 ‘strong buy' penny stocks with over 300% possible upside

Penny stocks are shares usually below $5, representing small companies, most of which trade by over-the-counter (OTC) transactions, while there

Date : 19/08/2022

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q1 2023 Results - Earnings Call Transcript

Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q1 2023 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Liz Williams - CFO Conference Call Participants Matt Biegler - Oppenheimer David Martin - Bloom Burton Catherine Novack - JonesTrading Arthur He - H.C. Wainwright Operator Greetings, and welcome to the Medicenna Therapeutics Corp. First Quarter Fiscal 2023 Earnings Call.

Date : 15/08/2022

Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022

TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 15, 2022 at 8:30 AM ET to report its first quarter fiscal 2023 financial results and operational highlights.

Date : 05/08/2022

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q4 2022 Results - Earnings Call Transcript

Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q4 2022 Earnings Conference Call June 22, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Martin Bexon - CMO Liz Williams - CFO Conference Call Participants Matt Biegler - Oppenheimer David Martin - Bloom Burton Catherine Novack - JonesTrading Swayampakula Ramakanth - H.C. Wainwright Andre Uddin - Mackie Research Capital Shubhendu Roy - Brookline Capital Markets David Bautz - Zacks Small-Cap Research Operator Hello, and welcome to the Medicenna Therapeutics Fiscal Year-End Earnings Call.

Date : 22/06/2022

Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022

TORONTO and HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on June 22, 2022 at 8:30 AM ET to report its fiscal year 2022 financial results and operational highlights.

Date : 07/06/2022





About Medicenna Therapeutics Corp.


CEO :
Sector : Healthcare
Industry : Biotechnology

Website : https://www.medicenna.com

Exchange : NASDAQ Capital Market

Description :

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.


My Newsletter

Sign Up For Updates & Newsletters